Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis

Objective. To evaluate the functional state of rheumatoid arthritis (RA) patients receiving Infliximab therapy (IF) in real clinical practice and its efficiency.
Subjects and methods. The analysis covered 225 patients receiving IF therapy, the follow-up duration in whom was 54 weeks. Disease activity was estimated by the DAS 28 index; functional status was assessed according to the Health Assessment Questionnaire (HAQ).
The authors made an analysis of a Per-Protocol (PP) population (n = 154) at 54 weeks of treatment and an analysis that could consider the results of treatment (by the ACR and EULAR criteria) in patients who had been withdrawn before the control time - a LOCF (Last Observation Carried Forward analysis) population.
Results. The mean age of the patients was 47.6±11.4 years; the duration of the disease was 7.8±6.4 years; DAS 28 activity scores were 6.6±1.1; the majority of patients had significant functional impairments (HAQ scores of 2.0±0.7), 86.7% of the patients had extraarticular manifestations; 79.6% were found to have rheumatoid factor (RF); the patients received an average of > 2 disease-modifying antirheumatic drugs (DMARDs).
After 2 week-therapy, there was a reduction in RA activity by DAS 28 index in both the PP (from 6.7±1.1 to 4.0±1.4) and LOCF (6.6±1.1 and 4.2±1.4; p < 106) populations.
Drug-induced remission (DAS 28 < 2.6) at 54 weeks was observed in 16.9 and 15.1% of the patients, respectively. Functional improvement was noted in the PP population: HAQ decreased from 2.0±0.7 to 1.7±0.7 scores by week 2; its reduction continued until week 14 (p < 0.05), by remaining stable later on. HAQ dropped from 2.0±0.7 to 1.2±0.7 scores in the LOCF population. At 54 weeks, normal population values of functional activity were achieved in 16.4%.
Log regression analysis in the LOCF population indicated that the previous use of DMARDs and a short history of the disease were predictors of an ACR70 response to IF therapy [OR=1.61 (1.13-2.30), p = 0.008 and OR = 0.91 (0.84-0.98), p = 0.018, respectively]. RF seronegativity was a predictor for achievement of low RA activity [OR = 0.44 (0.23-0.84)]. The previous use of glucocorticoids failed to increase the probability of a good response to IF therapy and achievement of clinical remission [OR = 0.26 (0.11-0.60), p = 0.001].
Conclusion. Therapy with IF in combination with methotrexate or other DMARDs reduces RA activity and improves the functional capacities of patients with RA in real clinical practice.

Infliximab, patients' functional state, registry of Infliximab

1. <div><p>Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 720 с.</p><p>Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. 2-е изд., доп. М.: Практическая медицина, 2009; 41-5.</p><p>Насонов Е.Л. Инновационные технологии в диагностике и лечении ревматических заболеваний (лекции цикла повышения квалификации врачей). М.: Изд-во АРР, 2009; 9,18.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004; 50: 1051-65.</p><p>Kavanaugh A., Han C., Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 849-55.</p><p>Han C., Smolen J., Kavanaugh A. et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthr Res Ther 2007; 9: R103.</p><p>Durez P., Nzeusseu Toukap A., Lauwerys B.R. A randomized comparative study of short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite metotrexate treatment. Ann Rheum Dis 2004; 63: 1069-74.</p><p>Lipsky P.E., van der Heijde D.M., St Clair E.W. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.</p><p>Амирджанова В.Н., Кайгородцева Е.Ю., Савенкова Н.А., Насонов Е.Л. Качество жизни как критерий эффективности терапии базисными противовоспалительными и генно-инженерными биологическими препаратами: результаты международных и российских исследований. Науч.-практич. ревматол. 2009; 2: 54-78.</p><p>Приказ МЗ СР РФ № 315н от 4 мая 2010 г. «Об утверждении Порядка оказания медицинской помощи больным с ревматическими заболеваниями» (Прил. 8).</p><p>Насонов Е.Л., Лукина Г.В., Сигидин Я.А. и др. Результаты Российского регистра применения препарата Инфликсимаб при ревматоидном артрите: Тезисы. М., 2009.</p><p>Лукина Г.В., Сигидин Я.А., Насонов Е.Л. Применение Инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра). Тер. арх. 2009; 81(8): 65-9.</p><p>Felson D.T., Anderson J.J., Boers M. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthr Rheum 1993; 36: 729-40.</p><p>Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995; 38: 44-8.</p><p>Fries J.F., Spitz P.W., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthr Rheum 1980; 23: 137-45.</p><p>Kosinski M., Zhao S.Z., Dedhiya S. et al. Determining minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthr Rheum 2000; 43(7): 1478-87.</p><p>Лечение ревматоидного артрита. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: Алмаз, 2006; 90-1.</p><p>Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М.: Ассоциация ревматологов России, 2007; 28 c.</p><p>Waladkhani A.R. Conducting Clinical Trials. A theoretical and practical guide. S. 1., 2008.</p></div><br />